MLYS (Mineralys Therapeutics) Institutional Ownership: 114.52% (As of Jul. 11, 2026)


MLYS Mineralys Therapeutics Inc MLYS
37 GF Score
Price $28.38
! 2 Warning Signs
View Full Analysis

What is Mineralys Therapeutics Institutional Ownership?

Mineralys Therapeutics MLYS -2.00% 37 Institutional Ownership is 114.52% as of Jul. 11, 2026. GuruFocus rates MLYS with a GF Score™ of 37/100. The stock has 2 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Mineralys Therapeutics's institutional ownership is 114.52%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Mineralys Therapeutics's Insider Ownership is 0.90%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Mineralys Therapeutics's Float Percentage Of Total Shares Outstanding is 83.48%.

Mineralys Therapeutics Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Mineralys Therapeutics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mineralys Therapeutics Institutional Ownership Chart

Mineralys Therapeutics Historical Data

The historical data trend for Mineralys Therapeutics can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 31.50 32.27 36.85 41.46 41.23 41.71 42.68 42.65 42.39 41.05
MLYS
37GF Score
Mineralys Therapeutics Inc MLYS
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mineralys Therapeutics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 114.52% mean?
Mineralys Therapeutics (MLYS) has a Institutional Ownership of 114.52% as of Jul. 11, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Mineralys Therapeutics and its competitors.
Is Mineralys Therapeutics' Institutional Ownership too high?
Mineralys Therapeutics' current Institutional Ownership is 114.52%. Overall, Mineralys Therapeutics has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Mineralys Therapeutics' Institutional Ownership compare to VCEL and NRIX?
Mineralys Therapeutics' Institutional Ownership of 114.52% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Mineralys Therapeutics and its competitors. Mineralys Therapeutics's current Institutional Ownership is 114.52%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mineralys Therapeutics stock overvalued right now?
Mineralys Therapeutics (MLYS) has a current Institutional Ownership of 114.52%. The current Institutional Ownership is 114.52%. Mineralys Therapeutics' overall GF Score™ is 37/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Mineralys Therapeutics (MLYS), the current Institutional Ownership is 114.52% as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Mineralys Therapeutics Business Description

Address 150 North Radnor Chester Road, Suite F200, Radnor, PA, USA, 19087
Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.
37GF Score

Get the complete analysis for MLYS

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$28.38
Price